Given our previous findings that fibrotic HOXA4 and SPRR1A were crucial direct and functional targets of miR-150 [17,18], circulating miR-150 levels in patients with MI can, thus, be used to guide future treatment strategies by modulating HOXA4 and SPRR1A. This evidence concerns the gene HOXA4 and myocardial infarction.